Skip to main content
Clinical Trials/NCT03857906
NCT03857906
Completed
N/A

Evaluation of Prophylactic Use of a Preoperative Intra-Aortic Ballon Pump in High-Risk Coronary Artery Bypass Graft Surgery: A Single-Centre Study

CMN "20 de Noviembre"0 sites129 target enrollmentOctober 21, 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Ischemic Cardiomyopathy
Sponsor
CMN "20 de Noviembre"
Enrollment
129
Primary Endpoint
30-Day All-Cause Mortality
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Background: The intra-aortic balloon balloon pump (IABP) has been used as a method of percutaneous circulatory assistance high surgical risk patients undergoing coronary artery bypass graft surgery (CABG); Although its applicability has been questioned by clinical trials showing poor impact to reduce the mortality due to cardiogenic shock associated with postoperative acute myocardial infarction (AMI), the real benefit reducing mortality in the postoperative context (PO) has not been determined examined through a prospective study with an adequate design.

Objective: To compare PO complications such as mortality, perioperative infarction and other complications in patients with high surgical risk undergoing CABG in comparison with controls.

Detailed Description

Methods: Quasi-experimental, prospective, comparative, non-randomized study. The decision to place the BIAC is not part of the study and depends on the multidisciplinary decision of a Heart Team, based on the individualized risk / benefit. The study population consists on high surgical risk patients with atherosclerotic coronary disease undergoing CABG in our centre between 2014-2018. Patients are excluded if any condition is present: cardiogenic shock, with AMI 48 hours prior and / or severe aortic insufficiency. In one group BIAC will be inserted 1-6 hours before surgery (BIAC group) and a second group is control (non-BIAC group). A minimum 30-day postoperative follow-up of will be performed, with primary end points (mortality and AMI type V) and secondary end points (additional PO complications). Analysis: An evaluation of normality distribution K-S will be performed, the means of quantitative (t-Test) and categorical variables (Fisher or χ² Pearson) will be compared. A multivariate analysis will be performed with linear logistic regression to evaluate the influence of age, sex, peripheral arterial disease (PAD) and EuroSCORE-II on the primary goal. Statistical significance will be considered when p \<0.05. Softwares: GraphPad-Prism-5.0 and SPSS-15.0

Registry
clinicaltrials.gov
Start Date
October 21, 2014
End Date
January 19, 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
CMN "20 de Noviembre"
Responsible Party
Principal Investigator
Principal Investigator

Héctor Hugo Escutia Cuevas

Clinical Professor

CMN "20 de Noviembre"

Eligibility Criteria

Inclusion Criteria

  • All patients greater than 18 years
  • Scheduled for coronary artery bypass graft (CABG) surgery were eligible
  • Multiple vessel disease with or without left main coronary artery (LMCA) significant stenosis (\>50%)
  • Written informed consent provided

Exclusion Criteria

  • Prior cardiogenic shock,
  • Acute myocardial infarction (AMI) less than 48 hours prior to enrollment
  • Previous IABP use
  • AMI mechanical complications
  • Aortic regurgitation greater than grade II in severity (on a scale of I to IV, with higher grades indicating more severe regurgitation)
  • Tachyarrhythmia
  • Other aortic procedures
  • Other non-CABG surgical procedures
  • Massive pulmonary embolism
  • Older than 90 years of age

Outcomes

Primary Outcomes

30-Day All-Cause Mortality

Time Frame: 30 days

30-Day Mortality

30-Day Postoperative Myocardial Infarction

Time Frame: 30 days

Based on the third universal definition on MI criteria

Secondary Outcomes

  • acute kidney injury(30 days)
  • 30-day occurrence rate of PCI(30 days)
  • Requirement of mechanical ventilation(30 days)
  • ICU length of stay(30 days)
  • Need for renal replacement therapy(30 days)
  • Postoperative use of inotropes and vasopressors(30 days)

Similar Trials